Novalpina buys majority stake in Laboratoire XO
UK-based private equity firm Novalpina Capital has acquired a majority stake in Laboratoire XO, a French pharmaceutical company focused on the production and distribution of prescription drugs treating chronic diseases.
More on Buyouts
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Main Capital's Assessio to be sold to Pollen Street
Recruitment software company tripled in revenue under Main Capital’s ownership
TPG takes majority control of A-Gas, doubles down on impact investing
KKR partially exits its 2017 investment in the specialty gas and chemical distributor, retaining a minority stake
Quadrivio to capitalise on baby boomers as it nears wrap for its new EUR 300m fund
The Silver Economy Fund makes its second investment as it highlights trend of GPs doubling down on narrow strategies
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds